Elmisol, levamisole HCl, 5, 10, 25 and 50 mg coated tablets
Orphan Drug Designation EU/3/05/324
Levamisole 5, 10, 25 and 50 mg (as Levamisole HCl)
Steroid-sensitive nephrotic syndrome
Below 25 ⁰C
Elmisol (levamisole HCl) is prescribed for the treatment of steroid-sensitive nephrotic syndrome (SSNS) in children.
Elmisol is available in four strengths: 5, 10, 25 and 50 mg. The tablets are increasing in size (minitabs of 5, 6, 7 and 8 mm).
Elmisol is an unlicensed medicine in the Netherlands. The Dutch Health Care Inspectorate (IGJ) has given permission for the supply.
In France, Elmisol has an ATU-status. Distribution to hospital pharmacies in France is carried out by Laboratoire Intsel Chimos, INRESA Pharma and Laboratoire Cevidra.
In the United Kingdom, (hospital) pharmacies that require Elmisol can contact Idis.
(Hospital) Pharmacies that would like to know more about the availability of this product outside these countries are welcome to contact us via our contact form. If you have ordered Elmisol with us before, please our order form to place a new order.
Since August 2018 the distribution activities of Orphan Drugs NL BV have been transferred to sister company Ace Pharmaceuticals BV.
Ace Pharmaceuticals has cooperated in the creation of publications about Levamisole. An overview with links to these publications is available here.